[EN] HCV NS3 PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASE NS3 DU VHC
申请人:MERCK SHARP & DOHME
公开号:WO2012040040A1
公开(公告)日:2012-03-29
The present invention relates to macrocyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
The present invention relates to macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
[EN] HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉASE NS3 DU VIRUS DE L'HÉPATITE C
申请人:MERCK SHARP & DOHME
公开号:WO2011014487A1
公开(公告)日:2011-02-03
The present invention relates to macrocyclic compounds of Formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
The present invention relates to macrocyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.